IntraTherapeutics, Inc., (ITI), a privately-held company engaged in the development, manufacturing and marketing of innovative medical devices for the peripheral vascular and peripheral non-vascular markets, announced today that it has entered into an exclusive, worldwide licensing agreement with American BioMed, Inc. (Woodlands, TX). The licensing agreement involves American BioMed's patent for a percutaneous guidewire microfilter. Terms of the agreement were not disclosed.
John Erb, president and CEO of IntraTherapeutics, stated: "This is an exciting opportunity for ITI. This micro-filter protection device will offer a tremendous advantage in improved safety to the patient by reducing the risk of stroke, limb loss, and heart attack during angioplasty and stenting procedures of the carotid, peripheral and coronary arteries. The micro-filter works by filtering emboli from the blood stream, while permitting blood flow during procedures performed by the interventional vascular physician."
IntraTherapeutics utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of peripheral vascular disease and non-vascular obstructions. ITI is ISO certified and has the CE Mark on several peripheral vascular stents for use in treating strictures in the subclavian, renal, iliac, femoral and popliteal arteries, and non-vascular stents, for biliary duct, esophagus, and colorectal obstructions. The company has attained FDA 510(k) market clearance for non-vascular stent use in the biliary duct and esophagus.